Research shows it promotes cell migration to injury sites, activates cells important for healing, and reduces inflammation and scarring aggregating the bodys repair cells precisely where theyre needed
Acute injury protocol: Weeks 12: 500mcg each peptide twice daily, localized + systemic Weeks 34: 500mcg each peptide once daily, systemic Weeks 56: 250mcg each peptide once daily, systemic Total duration: 6 weeks Chronic condition protocol: Weeks 14: 500mcg each peptide once daily Weeks 58: 250500mcg each peptide once daily (based on response) Weeks 912: 250mcg each peptide once daily or every other day Total duration: 12 weeks Post-surgical protocol: Days 17: 500mcg each peptide twice daily Weeks 24: 500mcg each peptide once daily Weeks 56: 250mcg each peptide once daily Total duration: 6 weeks Monitoring and Adjustments Protocols should track the following
Benzyl alcohol acts bacteriostatically , it does not kill bacteria immediately, but reliably suppresses their growth and multiplication
No completed human efficacy or safety trial
Known risks and side effects: Injection-site reactions (pain, redness, swelling, and induration) are the most consistently reported adverse effects across CJC-1295's human research and compounded/gray-market use